{"product_id":"anticancer-therapeutics-hardback-9780470723036","title":"Anticancer Therapeutics (Hardback) 9780470723036","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eAnticancer Therapeutics\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cfont size=\"4\"\u003eSotiris Missailidis (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780470723036, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 7 November 2008\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e424 pages\u003cbr\u003e24.4 x 16.8 x 2.7 cm, 0.822 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cem\u003e\u003cfont size=\"3\"\u003e“This book is very well conceived and well presented.” (\u003ci\u003eDoody's Reviews\u003c\/i\u003e, June 2009)  \u003cp\u003e\"This volume provides a comprehensive overview of the wealth of information now available in this important and fast-moving subject.\" (\u003ci\u003eAnticancer Research\u003c\/i\u003e, November - December 2008)\u003c\/p\u003e\u003c\/font\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003eKrebs steht bei den Todesursachen weltweit an zweiter Stelle. Die Forschung konzentriert sich zunehmend darauf, die Entstehung von Krebs ganzheitlich zu betrachten, bekannte Krebsmedikamente auf den Prüfstand zu stellen und Medikamente und kombinierte Therapieansätze zu entwickeln.\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003eForward xiii\u003c\/p\u003e \u003cp\u003eAcknowledgements xv\u003c\/p\u003e \u003cp\u003eList of contributors xvii\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection I: Development of Anticancer Therapeutics 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Exploring the Potential of Natural Products in Cancer Treatment 3\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eFotini N. Lamari and Paul Cordopatis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 3\u003c\/p\u003e \u003cp\u003e1.2 Sources 4\u003c\/p\u003e \u003cp\u003e1.3 Different Approaches to the Search for Bioactive Natural Products 6\u003c\/p\u003e \u003cp\u003e1.4 Methodologies of Lead Compound or New Drug Identification 10\u003c\/p\u003e \u003cp\u003e1.5 Chemoprevention – A New Area for Natural Product Research 13\u003c\/p\u003e \u003cp\u003e1.6 Concluding Remarks 13\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Combinatorial Approaches to Anticancer Drug Design 17\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSotiris Missailidis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 17\u003c\/p\u003e \u003cp\u003e2.2 Combinatorial Approaches for Small Molecule Drug Design 17\u003c\/p\u003e \u003cp\u003e2.3 Display Technologies 21\u003c\/p\u003e \u003cp\u003e2.4 Aptamer Selection 23\u003c\/p\u003e \u003cp\u003e2.5 Conclusions 27\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Rational Approaches to Anticancer Drug Design\/in silico Drug Development 29\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eStefano Alcaro, Anna Artese and Francesco Ortuso\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 29\u003c\/p\u003e \u003cp\u003e3.2 Approaches to the Drug Discovery Process in Anticancer Research 31\u003c\/p\u003e \u003cp\u003e3.3 Ligand-based Examples 32\u003c\/p\u003e \u003cp\u003e3.4 Structure-based Examples 36\u003c\/p\u003e \u003cp\u003e3.5 Conclusions 44\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection II: Anticancer Therapeutics 47\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Introduction to Anticancer Therapeutics 49\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eTeni Boulikas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Problems in cancer 49\u003c\/p\u003e \u003cp\u003e4.2 Cancer treatments 51\u003c\/p\u003e \u003cp\u003e4.3 Classification of chemotherapy drugs 53\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Platinum Drugs 55\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eTeni Boulikas, Alexandros Pantos, Evagelos Bellis and Petros Christofis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Cisplatin 55\u003c\/p\u003e \u003cp\u003e5.2 Lipoplatin 57\u003c\/p\u003e \u003cp\u003e5.3 Carboplatin 61\u003c\/p\u003e \u003cp\u003e5.4 Oxaliplatin 62\u003c\/p\u003e \u003cp\u003e5.5 Lipoxal 62\u003c\/p\u003e \u003cp\u003e5.6 New Platinum Compounds 64\u003c\/p\u003e \u003cp\u003e5.7 Cisplatin Resistance and Chemotherapy 70\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Antimicrotubule Agents 79\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eIain Brown, Jay N Sangrithi-Wallace and Andrew C Schofield\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Taxanes 79\u003c\/p\u003e \u003cp\u003e6.2 Vinca Alkaloids 82\u003c\/p\u003e \u003cp\u003e6.3 Mechanisms of Resistance to Antimicrotubule Agents 86\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Antimetabolites in Cancer Therapy 91\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJessica Scaife and David Kerr\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 91\u003c\/p\u003e \u003cp\u003e7.2 Folate Antagonists 92\u003c\/p\u003e \u003cp\u003e7.3 Pyrimidine Antagonists 96\u003c\/p\u003e \u003cp\u003e7.4 Purine Antagonists 104\u003c\/p\u003e \u003cp\u003e7.5 Summary 109\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Antitumour Antibiotics 111\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eManuel M. Paz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 111\u003c\/p\u003e \u003cp\u003e8.2 Actinomycin 111\u003c\/p\u003e \u003cp\u003e8.3 Mitomycin c 112\u003c\/p\u003e \u003cp\u003e8.4 Bleomycin 115\u003c\/p\u003e \u003cp\u003e8.5 Anthracyclines 118\u003c\/p\u003e \u003cp\u003e8.6 Trabectedin (Ecteinascidin, ET-743) 121\u003c\/p\u003e \u003cp\u003e8.7 Camptothecins 123\u003c\/p\u003e \u003cp\u003e8.8 Podophyllotoxins 124\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Alkylating Agents 133\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAna Paula Francisco, Maria de Jesus Perry, Rui Moreira and Eduarda Mendes\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction 133\u003c\/p\u003e \u003cp\u003e9.2 Nitrogen Mustards 133\u003c\/p\u003e \u003cp\u003e9.3 Methylmelamines and Ethylenimines 140\u003c\/p\u003e \u003cp\u003e9.4 Methylhydrazine Derivatives 141\u003c\/p\u003e \u003cp\u003e9.5 Alkylsulfonates 143\u003c\/p\u003e \u003cp\u003e9.6 Nitrosoureas 144\u003c\/p\u003e \u003cp\u003e9.7 Triazenes 149\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Hormone Therapies 159\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eGeorge C. Zografos, Nikolaos V. Michalopoulos and Flora Zagouri\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 159\u003c\/p\u003e \u003cp\u003e10.2 Oestrogen Receptor Targeted Therapeutics 160\u003c\/p\u003e \u003cp\u003e10.3 Progesterone-Targeted Therapy 174\u003c\/p\u003e \u003cp\u003e10.4 Neuroendocrine Tumours 176\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Photodynamic Therapy of Cancer 187\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eK. Eszter Borbas and Dorothée Lahaye\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 187\u003c\/p\u003e \u003cp\u003e11.2 Photosensitizers 196\u003c\/p\u003e \u003cp\u003e11.3 Outlook 212\u003c\/p\u003e \u003cp\u003e11.4 Acknowledgement 212\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Target-directed Drug Discovery 223\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eTracey D. Bradshaw\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction 223\u003c\/p\u003e \u003cp\u003e12.2 Tyrosine Kinases – Role and Significance in Cancer 226\u003c\/p\u003e \u003cp\u003e12.3 Targeted Therapy for the Treatment of Non-small Cell Lung Cancer (NSCLC) 226\u003c\/p\u003e \u003cp\u003e12.4 Targeted Therapy for the Treatment of Chronic Myeloid Leukaemia 229\u003c\/p\u003e \u003cp\u003e12.5 Targeted Therapy for the Treatment of Breast Cancer 230\u003c\/p\u003e \u003cp\u003e12.6 Angiogenesis 231\u003c\/p\u003e \u003cp\u003e12.7 Targeting Cell Cycling 235\u003c\/p\u003e \u003cp\u003e12.8 Targeting Apoptosis 237\u003c\/p\u003e \u003cp\u003e12.9 Targeting mTOR 237\u003c\/p\u003e \u003cp\u003e12.10 The Future of Molecularly Targeted Therapy 238\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Tumour Hypoxia: Malignant Mediator 245\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJill L. O’Donnell, Aoife M. Shannon, David Bouchier-Hayes\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 245\u003c\/p\u003e \u003cp\u003e13.2 Hypoxia Inducible Factor-1 and Hypoxia 246\u003c\/p\u003e \u003cp\u003e13.3 HIF-1α Post-translational Changes 247\u003c\/p\u003e \u003cp\u003e13.4 How Genetics Can Modify HIF 248\u003c\/p\u003e \u003cp\u003e13.5 How Tumours Overcome Hypoxia with HIF- 1 249\u003c\/p\u003e \u003cp\u003e13.6 HIF-1 Therapeutics 252\u003c\/p\u003e \u003cp\u003e13.7 Conclusion 255\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Resistance to Chemotherapy Drugs 263\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eRobert O’Connor and Laura Breen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Introduction 263\u003c\/p\u003e \u003cp\u003e14.2 What are the Factors Limiting the Efficacy of Cancer Chemotherapy Treatment? 263\u003c\/p\u003e \u003cp\u003e14.3 A Classification of the Important Chemotherapy Resistance Mechanisms 265\u003c\/p\u003e \u003cp\u003e14.4 Illustrative Mechanisms of Pharmacokinetic Resistance 267\u003c\/p\u003e \u003cp\u003e14.5 Illustrative Mechanisms of Pharmacodynamic Resistance 273\u003c\/p\u003e \u003cp\u003e14.6 Conclusion 277\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Cancer Immunotherapy 283\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMaria Belimezi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 The Molecular Basis of Cancer Immunotherapy and Gene Immunotherapy of Cancer 283\u003c\/p\u003e \u003cp\u003e15.2 Recombinant Monoclonal Antibodies 284\u003c\/p\u003e \u003cp\u003e15.3 Cell Immunotherapy 292\u003c\/p\u003e \u003cp\u003e15.4 Cancer Vaccines 296\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Gene Therapy 305\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMaria Belimezi, Teni Boulikas and Michael L. Roberts\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 The Concept of Gene Therapy 305\u003c\/p\u003e \u003cp\u003e16.2 Steps for Successful Gene Therapy 306\u003c\/p\u003e \u003cp\u003e16.3 Retroviruses in Cancer Gene Therapy 307\u003c\/p\u003e \u003cp\u003e16.4 Adenoviruses in Cancer Gene Therapy 308\u003c\/p\u003e \u003cp\u003e16.5 Gene Therapy of Cancer 310\u003c\/p\u003e \u003cp\u003e16.6 Cancer Immunotherapy with Cytokine Genes 311\u003c\/p\u003e \u003cp\u003e16.7 IL-12 in Cancer Immunotherapy 311\u003c\/p\u003e \u003cp\u003e16.8 Viruses able to Kill Cancer Cells 314\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Antisense Agents 317\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eHuma Khan and Sotiris Missailidis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17.1 Introduction 317\u003c\/p\u003e \u003cp\u003e17.2 Traditional Antisense Oligonucleotides (ASOs) 318\u003c\/p\u003e \u003cp\u003e17.3 Ribozymes and DNAzymes 320\u003c\/p\u003e \u003cp\u003e17.4 RNA Interference and siRNAs 321\u003c\/p\u003e \u003cp\u003e17.5 Shortcomings of Antisense Therapeutics 322\u003c\/p\u003e \u003cp\u003e17.6 Antisense Agents in Clinical Trials 324\u003c\/p\u003e \u003cp\u003e17.7 Concluding Remarks 329\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Aptamers as Anticancer Agents 331\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eVaidehi Makwana, Suzanne Simmons and Sotiris Missailidis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18.1 Introduction 331\u003c\/p\u003e \u003cp\u003e18.2 Aptamers in Cancer 332\u003c\/p\u003e \u003cp\u003e18.3 Final comments 341\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection III: Other Aspects in Anticancer Therapeutic Development 347\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Treatment of Cancer in Conjunction with Other Agents 349\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eGary Robert Smith\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19.1 Introduction 349\u003c\/p\u003e \u003cp\u003e19.2 Non-steroidal Anti-inflammatory Drugs 353\u003c\/p\u003e \u003cp\u003e19.3 Angiotensin-converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockade 358\u003c\/p\u003e \u003cp\u003e19.4 Partners in Crime – Dealing with Co-infections 362\u003c\/p\u003e \u003cp\u003e19.5 Discussion 363\u003c\/p\u003e \u003cp\u003e\u003cb\u003e20 Clinical Trials in Oncology 365\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eTim Friede, Janet Dunn and Nigel Stallard\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20.1 Clinical Trials 365\u003c\/p\u003e \u003cp\u003e20.2 Early-Phase (Phase I and Phase II) Clinical Trials in Oncology 368\u003c\/p\u003e \u003cp\u003e20.3 Confirmatory (Phase III) Trials in Oncology 371\u003c\/p\u003e \u003cp\u003e20.4 Further Issues in Clinical Trials in Oncology 374\u003c\/p\u003e \u003cp\u003e\u003cb\u003e21 Representative Cancers, Treatment and Market 377\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eTeni Boulikas and Nassos Alevizopoulos\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21.1 Lung Cancer 377\u003c\/p\u003e \u003cp\u003e21.2 Breast Cancer 378\u003c\/p\u003e \u003cp\u003e21.3 Prostate Cancer 378\u003c\/p\u003e \u003cp\u003e21.4 Colorectal Cancer 379\u003c\/p\u003e \u003cp\u003e21.5 Ovarian Cancer 380\u003c\/p\u003e \u003cp\u003e21.6 Pancreatic Cancer 380\u003c\/p\u003e \u003cp\u003e21.7 Gastric Cancer 381\u003c\/p\u003e \u003cp\u003e21.8 Combination Chemotherapy 382\u003c\/p\u003e \u003cp\u003e21.9 The Pharmaceutical World of Anticancer Drugs 383\u003c\/p\u003e \u003cp\u003e\u003cb\u003e22 Future Trends in Cancer Therapeutics 387\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSotiris Missailidis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22.1 Introduction 387\u003c\/p\u003e \u003cp\u003e22.2 Personalized Medicines 388\u003c\/p\u003e \u003cp\u003e22.3 Delivery Systems 390\u003c\/p\u003e \u003cp\u003e22.4 Closing Remarks 391\u003c\/p\u003e \u003cp\u003eIndex 393\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Biology, life sciences [\u003ca title=\"See our other books on Biology, life sciences\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Biology,%20life%20sciences%20%5BPS%5D%22\"\u003ePS\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley","offers":[{"title":"Brand New","offer_id":52278024339736,"sku":"9780470723036","price":139.97,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9780470723036.jpg?v=1781456116","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/anticancer-therapeutics-hardback-9780470723036","provider":"Freshly Printed Books","version":"1.0","type":"link"}